The soluble CD163 (sCD163) was elevated in systemic lupus erythematosus (SLE) patients.
Purpose
To study whether serum sCD163 could be used to predict the occurrence and prognosis of lupus nephritis (LN).
Research Design
The recruited patients were classified into different groups according to standard identification criteria.
Study Sample
The patients with LN.
Data Collection and Analysis
11 indices were analyzed and compared in SLE and LN patients. Furthermore, the level of serum sCD163 was detected using an enzyme-linked immunosorbent assay. Meanwhile, the receiver operating characteristic analysis was performed to evaluate the prediction effect of sCD163. Additionally, spearman correlation analysis of serum sCD163 with indices was conducted.
Results
There were six positive indices and one negative risk factor correlated to LN. sCD163 was elevated in LN patients and could be used to diagnose LN. Importantly, sCD163 was increased in LN patients with a heavy SLE disease activity index. Finally, it was revealed that the level of sCD163 was higher in the LN patients with no response than that with complete or partial response, which also could predict the prognosis of LN.
Conclusions
Serum sCD163 was elevated in LN patients than in SLE patients, which could be used to predict the occurrence and prognosis of LN.
KiriakidouMChingCL. Systemic lupus erythematosus. Ann Intern Med2020; 172: ITC81–ITC96.
2.
TsokosGC. Systemic lupus erythematosus. N Engl J Med2011; 365: 2110–2121.
3.
BastianHMRosemanJMMcGwinGJr, et al.Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus2002; 11: 152–160.
4.
ManingdingEDall’EraMTrupinL, et al.Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: the California lupus surveillance project. Arthritis Care Res2020; 72: 622–629.
5.
Hernandez CruzBAlonsoFCalvo AlenJ, et al.Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry). Lupus2020; 29: 27–36.
PulfordKMicklemKMcCarthyS, et al.A monocyte/macrophage antigen recognized by the four antibodies GHI/61, Ber-MAC3, Ki-M8 and SM4. Immunology1992; 75: 588–595.
8.
NielsenMCHvidbjerg GantzelRClariaJ, et al.Macrophage activation markers, CD163 and CD206, in acute-on-chronic liver failure. Cells2020; 9: 1175.
9.
EtzerodtAManieckiMBMollerK, et al.Tumor necrosis factor α-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol2010; 88: 1201–1205.
10.
ChoiMYFloodKBernatskyS, et al.A review on SLE and malignancy. Best Pract Res Clin Rheumatol2017; 31: 373–396.
11.
NakayamaWJinninMMakinoK, et al.CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus. Eur J Dermatol2012; 22: 512–517.
12.
ZizzoGGuerrieriJDittmanLM, et al.Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther2013; 15: R212.
13.
LakosGGonzalezMFlahertyD, et al.Detection of anti-dsDNA antibodies by computer-aided automated immunofluorescence analysis. J Immunol Methods2016; 433: 17–22.
14.
AustinHA3rdMuenzLRJoyceKM, et al.Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int1984; 25: 689–695.
15.
BajemaIMWilhelmusSAlpersCE, et al.Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int2018; 93: 789–796.
16.
JakesRWBaeSCLouthrenooW, et al.Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res2012; 64: 159–168.
17.
TektonidouMGDasguptaAWardMM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol2016; 68: 1432–1441.
18.
CostenbaderKHDesaiAAlarconGS, et al.Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum2011; 63: 1681–1688.
19.
BarsalouJBradleyTJTyrrellPN, et al.Impact of disease duration on vascular surrogates of early atherosclerosis in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol2016; 68: 237–246.
20.
GaoNKongMLiX, et al.Systemic lupus erythematosus and cardiovascular disease: a Mendelian randomization study. Front Immunol2022; 13: 908831.
21.
ParperisKVelidakisNKhattabE, et al.Systemic lupus erythematosus and pulmonary hypertension. Int J Mol Sci2023; 24: 5085.
22.
MansonJJMaARogersP, et al.Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther2009; 11: R154.
23.
RekvigOP. Autoimmunity and SLE: factual and semantic evidence-based critical analyses of definitions, etiology, and pathogenesis. Front Immunol2020; 11: 569234.
24.
RekvigOP. The dsDNA, anti-dsDNA antibody, and lupus nephritis: what we agree on, what must be done, and what the best strategy forward could Be. Front Immunol2019; 10: 1104.
25.
Hye KhanMAStavniichukASattarMA, et al.Epoxyeicosatrienoic acid analog EET-A blunts development of lupus nephritis in mice. Front Pharmacol2019; 10: 512.
26.
MahajanAAmelioJGairyK, et al.Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus2020; 29: 1011–1020.
27.
Al ArfajASKhalilN. Levels of proteinuria and renal pathology in systemic lupus erythematosus patients. Saudi J Kidney Dis Transpl2023; 34: 154–160.
28.
ZhouZJardineMJLiQ, et al.Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke2021; 52: 1545–1556.
29.
YangGGuoNYinJ, et al.Elevated soluble CD163 predicts renal function deterioration in lupus nephritis: a cohort study in Eastern China. J Int Med Res2021; 49: 3000605211049963.
30.
EndoNTsuboiNFuruhashiK, et al.Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. Nephrol Dial Transplant2016; 31: 2023–2033.
31.
Mejia-ViletJMZhangXLCruzC, et al.Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis. J Am Soc Nephrol2020; 31: 1335–1347.
32.
LiJYuYFLiuCH, et al.Significance of M2 macrophages in glomerulonephritis with crescents. Pathol Res Pract2017; 213: 1215–1220.
33.
HillGSDelahousseMNochyD, et al.Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int2001; 59: 304–316.
34.
OlmesGButtner-HeroldMFerrazziF, et al.CD163+ M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis. Arthritis Res Ther2016; 18: 90.
35.
CheunsuchonBIncharoenPChawanasuntorapojR, et al.Glomerular macrophage is an indicator of early treatment response in diffuse proliferative lupus nephritis. J Med Assoc Thai2013; 96(Suppl 2): S246–S251.
36.
SchifferLBethunaickanRRamanujamM, et al.Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol2008; 180: 1938–1947.
37.
Pérez de LemaGMaierHNietoE, et al.Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol2001; 12: 1369–1382.
38.
TeschGHMaifertSSchwartingA, et al.Monocyte chemoattractant protein 1-dependent Leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med1999; 190: 1813–1824.
39.
KulkarniOPawarRDPurschkeW, et al.Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol2007; 18: 2350–2358.
40.
VielhauerVAndersHJSchlondorffD. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin Nephrol2007; 27: 181–197.
41.
MantovaniASicaASozzaniS, et al.The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol2004; 25: 677–686.
42.
NdisangJFMishraM. The heme oxygenase system selectively suppresses the proinflammatory macrophage m1 phenotype and potentiates insulin signaling in spontaneously hypertensive rats. Am J Hypertens2013; 26: 1123–1131.
43.
ChengQMouLSuW, et al.Ferroptosis of CD163(+) tissue-infiltrating macrophages and CD10(+) PC(+) epithelial cells in lupus nephritis. Front Immunol2023; 14: 1171318.
44.
AllamMFathyHAllahDA, et al.Lupus nephritis: correlation of immunohistochemical expression of C4d, CD163-positive M2c-like macrophages and Foxp3-expressing regulatory T cells with disease activity and chronicity. Lupus2020; 29: 943–953.
45.
SandersfeldMButtner-HeroldMFerrazziF, et al.Macrophage subpopulations in pediatric patients with lupus nephritis and other inflammatory diseases affecting the kidney. Arthritis Res Ther2024; 26: 46.
46.
WynnTAChawlaAPollardJW. Macrophage biology in development, homeostasis and disease. Nature2013; 496: 445.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
